Logo image of QURE

UNIQURE NV (QURE) Stock Fundamental Analysis

NASDAQ:QURE - Nasdaq - NL0010696654 - Common Stock - Currency: USD

15.23  -0.27 (-1.74%)

After market: 15.1504 -0.08 (-0.52%)

Fundamental Rating

3

Taking everything into account, QURE scores 3 out of 10 in our fundamental rating. QURE was compared to 561 industry peers in the Biotechnology industry. QURE has a bad profitability rating. Also its financial health evaluation is rather negative. QURE shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year QURE has reported negative net income.
QURE had a negative operating cash flow in the past year.
QURE had negative earnings in 4 of the past 5 years.
In the past 5 years QURE reported 4 times negative operating cash flow.
QURE Yearly Net Income VS EBIT VS OCF VS FCFQURE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M

1.2 Ratios

QURE has a Return On Assets (-35.94%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -645.89%, QURE is doing worse than 81.82% of the companies in the same industry.
Industry RankSector Rank
ROA -35.94%
ROE -645.89%
ROIC N/A
ROA(3y)-32.71%
ROA(5y)-18.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
QURE Yearly ROA, ROE, ROICQURE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

QURE has a better Gross Margin (53.97%) than 77.18% of its industry peers.
QURE's Gross Margin has declined in the last couple of years.
QURE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.17%
GM growth 5YN/A
QURE Yearly Profit, Operating, Gross MarginsQURE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

3

2. Health

2.1 Basic Checks

QURE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, QURE has more shares outstanding
Compared to 5 years ago, QURE has more shares outstanding
The debt/assets ratio for QURE is higher compared to a year ago.
QURE Yearly Shares OutstandingQURE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
QURE Yearly Total Debt VS Total AssetsQURE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

QURE has an Altman-Z score of -1.91. This is a bad value and indicates that QURE is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.91, QURE is in line with its industry, outperforming 55.26% of the companies in the same industry.
QURE has a Debt/Equity ratio of 14.79. This is a high value indicating a heavy dependency on external financing.
QURE has a worse Debt to Equity ratio (14.79) than 85.38% of its industry peers.
Industry RankSector Rank
Debt/Equity 14.79
Debt/FCF N/A
Altman-Z -1.91
ROIC/WACCN/A
WACC7.04%
QURE Yearly LT Debt VS Equity VS FCFQURE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

QURE has a Current Ratio of 11.99. This indicates that QURE is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 11.99, QURE belongs to the best of the industry, outperforming 84.14% of the companies in the same industry.
QURE has a Quick Ratio of 11.99. This indicates that QURE is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 11.99, QURE belongs to the best of the industry, outperforming 84.14% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.99
Quick Ratio 11.99
QURE Yearly Current Assets VS Current LiabilitesQURE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

QURE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.00%, which is quite impressive.
QURE shows a small growth in Revenue. In the last year, the Revenue has grown by 6.43%.
Measured over the past years, QURE shows a very strong growth in Revenue. The Revenue has been growing by 30.01% on average per year.
EPS 1Y (TTM)29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.71%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y-62.73%
Revenue growth 5Y30.01%
Sales Q2Q%-81.53%

3.2 Future

Based on estimates for the next years, QURE will show a very strong growth in Earnings Per Share. The EPS will grow by 26.26% on average per year.
Based on estimates for the next years, QURE will show a very strong growth in Revenue. The Revenue will grow by 81.90% on average per year.
EPS Next Y25.99%
EPS Next 2Y19.16%
EPS Next 3Y15.1%
EPS Next 5Y26.26%
Revenue Next Year8.22%
Revenue Next 2Y75.09%
Revenue Next 3Y51.11%
Revenue Next 5Y81.9%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
QURE Yearly Revenue VS EstimatesQURE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
QURE Yearly EPS VS EstimatesQURE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for QURE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QURE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QURE Price Earnings VS Forward Price EarningsQURE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QURE Per share dataQURE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

QURE's earnings are expected to grow with 15.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.16%
EPS Next 3Y15.1%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for QURE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UNIQURE NV

NASDAQ:QURE (5/22/2025, 5:59:44 PM)

After market: 15.1504 -0.08 (-0.52%)

15.23

-0.27 (-1.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2025-05-09/bmo
Earnings (Next)N/A N/A
Inst Owners77.83%
Inst Owner Change17.3%
Ins Owners1.69%
Ins Owner Change2.66%
Market Cap833.54M
Analysts84
Price Target36.63 (140.51%)
Short Float %11.21%
Short Ratio2.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-59.79%
Min EPS beat(2)-139.62%
Max EPS beat(2)20.04%
EPS beat(4)3
Avg EPS beat(4)-24.71%
Min EPS beat(4)-139.62%
Max EPS beat(4)20.04%
EPS beat(8)3
Avg EPS beat(8)-49%
EPS beat(12)6
Avg EPS beat(12)-26.16%
EPS beat(16)9
Avg EPS beat(16)0.65%
Revenue beat(2)0
Avg Revenue beat(2)-73.43%
Min Revenue beat(2)-75.51%
Max Revenue beat(2)-71.35%
Revenue beat(4)1
Avg Revenue beat(4)-38.87%
Min Revenue beat(4)-75.51%
Max Revenue beat(4)58.38%
Revenue beat(8)3
Avg Revenue beat(8)-37.37%
Revenue beat(12)4
Avg Revenue beat(12)-14.89%
Revenue beat(16)6
Avg Revenue beat(16)15.2%
PT rev (1m)-0.53%
PT rev (3m)-0.75%
EPS NQ rev (1m)11.06%
EPS NQ rev (3m)-3.09%
EPS NY rev (1m)7.96%
EPS NY rev (3m)-6.41%
Revenue NQ rev (1m)-4.61%
Revenue NQ rev (3m)0.72%
Revenue NY rev (1m)-3.36%
Revenue NY rev (3m)21.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 41.26
P/FCF N/A
P/OCF N/A
P/B 24.74
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.41
EYN/A
EPS(NY)-2.87
Fwd EYN/A
FCF(TTM)-3.06
FCFYN/A
OCF(TTM)-3.04
OCFYN/A
SpS0.37
BVpS0.62
TBVpS-1.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.94%
ROE -645.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.97%
FCFM N/A
ROA(3y)-32.71%
ROA(5y)-18.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.17%
GM growth 5YN/A
F-Score5
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 14.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.91%
Cap/Sales 5.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.99
Quick Ratio 11.99
Altman-Z -1.91
F-Score5
WACC7.04%
ROIC/WACCN/A
Cap/Depr(3y)98.33%
Cap/Depr(5y)124.6%
Cap/Sales(3y)24.73%
Cap/Sales(5y)20.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.71%
EPS Next Y25.99%
EPS Next 2Y19.16%
EPS Next 3Y15.1%
EPS Next 5Y26.26%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y-62.73%
Revenue growth 5Y30.01%
Sales Q2Q%-81.53%
Revenue Next Year8.22%
Revenue Next 2Y75.09%
Revenue Next 3Y51.11%
Revenue Next 5Y81.9%
EBIT growth 1Y36.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.12%
EBIT Next 3Y6.1%
EBIT Next 5Y49.92%
FCF growth 1Y21.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.91%
OCF growth 3YN/A
OCF growth 5YN/A